Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 17/20 | 0.76 |
| ▸ | MMP13 | P45452 | 16/20 | 0.76 |
| ▸ | MMP2 | P08253 | 5/20 | 0.60 |
| ▸ | MMP9 | P14780 | 5/20 | 0.60 |
| ▸ | MMP3 | P08254 | 3/20 | 0.60 |
| ▸ | MMP8 | P22894 | 3/20 | 0.60 |
| ▸ | MMP14 | P50281 | 2/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3855639 | 0.89 | MMP1 (0.76) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL28722341 | 0.87 | MMP13 (0.57) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6994423 | 0.86 | MMP1 (1.00) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6994418 | 0.86 | MMP1 (1.00) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL5482672 | 0.86 | MMP1 (0.56) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL3874407 | 0.78 | MMP1 (0.76) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL28707435 | 0.77 | MMP1 (0.56) | MMP1MMP13MMP2MMP9MMP3 | |
| Hydroxyamine SCHEMBL19181460 | 0.77 | MMP1 (0.77) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL7004525 | 0.77 | MMP1 (0.80) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL4048453 | 0.77 | MMP1 (0.80) | MMP1MMP13MMP2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037404-B2 | Human monoclonal antibodies against EphA4 and their use | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-07-16 | — | — | US | disclosed |
| EP-3473271-B1 | HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE | US GOV HEALTH & HUMAN SERVICES (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11078260-B2 | Antibodies to endoplasmin and their use | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210171645-A1 | HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-06-10 | — | — | US | disclosed |
| US-10934360-B2 | Human monoclonal antibodies against EPHA4 and their use | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-03-02 | — | — | US | disclosed |
| EP-3177320-B1 | HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE | US GOV HEALTH & HUMAN SERVICES (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3473271-A1 | HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190040141-A1 | METHODS AND COMPOSITIONS FOR TREATING TUMOR DISEASES | AMGEN INC (US) | 2019-02-07 | — | — | US | disclosed |
| EP-2129397-B1 | METHODS AND COMPOSITIONS FOR TREATING TUMOR DISEASES | AMGEN INC (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-3135692-B1 | ANTIBODIES TO ENDOPLASMIN AND THEIR USE | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20050244408-A1 | gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies; colorectal or breast cancer tumor | COHEN BRUCE D | 2005-11-03 | — | — | US | disclosed |
| EP-1575592-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050069539-A1 | Modified human IGF-IR antibodies | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
| WO-2005016967-A2 | MODIFIED HUMAN IGF-1R ANTIBODIES | PFIZER PRODUCTS INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040202655-A1 | Antibodies to IGF-I receptor for the treatment of cancers | PHARMACIA CORPORATION | 2004-10-14 | — | — | US | disclosed |
| US-20040166544-A1 | Antibodies to c-Met for the treatment of cancers | PHARMACIA CORPORATION | 2004-08-26 | — | — | US | disclosed |
| WO-2004054585-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040086503-A1 | High-affinity human anti-IGF-IR antibodies that could be used to treat diseases in humans | AMGEN FREMONT INC. | 2004-05-06 | — | — | US | disclosed |
| EP-1399483-A2 | ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR | PFIZER INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002053596-A2 | ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR | PFIZER INC. (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040202655-A1 | Antibodies to IGF-I receptor for the treatment of cancers | IGF1R, IGFBP1, IGFBP2 | MMP1 993/4885MMP13 1447/4885MMP2 1077/4885 |
| US-20040166544-A1 | Antibodies to c-Met for the treatment of cancers | MET, HGF, HGFAC | MMP1 3974/4885MMP13 1212/4885MMP2 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.